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ABSTRACT 
This study was performed to determine the association amongst serum leptin level and anthropometric measures with 
the severity of Diabetic Retinopathy (DR) in subjects with type 2 Diabetes Mellitus (DM). This case-controlled study was 
conducted within a one-year period, during year 2016, at outpatient retina ophthalmology clinics of Shiraz, southern 
Iran. Eighty-three patients with type 2 DM, referring for ophthalmoscopy evaluation, were included. Anthropometric 
measures, serum leptin level, and baseline laboratory assessment was performed for all subjects. Patients were 
categorized as group 1, consisting of patients with severe Non-Proliferative Diabetic Retinopathy (severe NPDR) and 
Proliferative Diabetic Retinopathy (PDR) (n = 44), and group 2, consisting of patients without Diabetic Retinopathy (no 
DR) or mild/moderate NPDR (n = 39). The serum leptin level and anthropometric measures were compared between the 
two study groups. The correlation between these variables was also assessed. The mean age of the participants was 59.3 
± 6.9 years old. The two study groups were comparable regarding baseline characteristics. Cases of group 1 had 
significantly higher Erythrocyte Sedimentation Rate (ESR) (P = 0.049) and Systolic Blood Pressure (P = 0.025) when 
compared with those of group 2. The serum level of leptin was found to be significantly higher in cases of group 1 when 
compared to those of group 2 (P = 0.003). However, anthropometric measures, including Body Mass Index (BMI) (P = 
0.167), Body Adiposity Index (BAI) (P = 0.061), and Waist to Hip Ratio (WHR) (P = 0.220) were comparable between the 
two study groups. Serum leptin level was positively correlated with BMI (r = 0.819; P < 0.001) and BAI (r = 0.630; P < 
0.001) in group 1. Increased serum levels of leptin were associated with advanced stages of DR in subjects with type 2 
DM. Serum leptin level might be a better indicator of the effects of obesity on DR, compared to anthropometric 
measures (BAI or BMI). 
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INTRODUCTION
Diabetic retinopathy (DR) is considered an important and 
devastating microvascular complication of Diabetes 
Mellitus (DM). Proliferative diabetic retinopathy (PDR) is 
associated with decreased visual acuity, retinal 
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detachment, hemorrhage, and complete loss of vision [1-
3]. The prevalence of DRwas reported as 37% in patients 
with type 2 DM, from whom 27.3% had Non-Proliferative 
(NPDR) and 9.6% had PDR. The prevalence of Clinically 
Significant Macular Edema (CSME) and sight threatening 
retinopathy was reported as 5.8% and 14.0%, 
respectively [4, 5]. Hypertension, anemia, renal failure, 
serum level of Hemoglobin A1C (HbA1C), age, type of DM, 
renal disease, physical inactivity, and inflammatory 
biomarkers were determined as risk factors for DR in 
patients with DM [6, 7]. Obesity is a morbid state, 
affecting many organs and many of the risk factors of DR. 
Metabolic syndrome is characterized by obesity, insulin 
resistance, hyperinsulinemia, hypertension, 
hyperlipidemia, and inflammation, which result in 
endothelial dysfunction and pathogenesis of DR [8]. It 
has been well-demonstrated that DR is associated with 
obesity, determined by Body Mass Index (BMI), Visceral 
Fat Accumulation (VFA), and Body Adiposity Index (BAI) 
[9-11]. Several lines of evidence have demonstrated that 
adipocytokines have pathophysiologic roles in 
complications related to obesity. Leptin is an 
adipocytokine that acts directly on the hypothalamus. It 
regulates energy expenditure and food intake [12]. 
Serum levels of leptin have been associated with obesity 
and obesity-associated microvascular complications [13, 
14]. Evidence has also suggested the role of leptin in the 
pathogenesis of DR. It has been demonstrated that 
serum levels of leptin are associated with proliferative 
retinopathy, when compared with non-proliferative 
retinopathy [15-17]. In addition, vitreous levels of leptin 
are higher in those with PDR or retinal detachment [18, 
19]. However, controversy still exists in this regard, while 
some studies have failed to demonstrate any association 
between serum leptin levels and DR [20]. Thus, the 
search for the role of leptin in pathogenesis of DR is still 
underway. The aim of the current study was to 
determine the association amongst serum leptin levels 
and anthropometric measures (BMI, BAI, and Waist to 
Hip Ratio) with the severity of DRin subjects with type 2 
DM. 
MATERIALS AND METHODS 
This case-controlled study was conducted at Poostchi 
outpatient ophthalmology clinic, affiliated to Shiraz 
University of Medical Sciences, Shiraz, Southern Iran, 
during a one-year period, form February, 2016 to 
February, 2017. The study protocol was approved by the 
Institutional Review Board (IRB) and the medical ethics 
committee of Shiraz University of Medical Sciences and 
all patients provided informed written consents before 
being included in the study. This study included adult 
(>18 years) patients with type 2 DM, referring to the 
clinic of study during the study period for screening of 
DR. The diagnosis of DM was based on standard criteria 
by two endocrinologists. This study excluded those with 
type 1 DM, renal impairment with an estimated 
Glomerular Filtration Rate (eGFR) of <30 mL/min/1.73 
m
2
, secondary hypertension (renal vascular hypertension, 
primary aldosteronism, pheochromocytoma, and 
hyperthyroidism), liver dysfunction, chronic pulmonary 
disease, arteriosclerotic obliterans, severe anemia, sleep 
apnea syndrome, and symptomatic cerebrovascular 
disease. Those taking thiazolidinediones and 
corticosteroids, pregnant subjects, those with 
malignancies or immunodeficiency, were also excluded. 
All patients were evaluated initially and medical history 
and physical examination findings were recorded. The 
demographic data, weight, height, hip diameter, waist 
circumference, drug history, and DM duration were also 
recorded. The BMI was calculated as the weight in 
kilograms divided by the square of the height in meters. 
Waist to Hip Ratio (WHR) was also used as an index of 
obesity. Furthermore, BAI was calculated by a formula 
suggested by Bergman et al. [21]. 
All patients underwent complete ophthalmoscopic 
examination, including air puff applanation tonometry, 
slit lamp biomicroscopy, binocular indirect slit lamp 
fundoscopy, and fundus photography, after mydriasis 
was performed. Color fundus photographs of two fields, 
which included macular field and disc/nasal field of both 
eyes, were taken using a 45° fundus camera (DRS: Digital 
Retinography System). The physical examination as well 
as the two-field 45° fundus photography and standard 
photographs were used to grade retinal lesions, 
according to international clinical disease severity scale 
based on the Wisconsin Epidemiologic Study of Diabetic 
Retinopathy (WESDR) and Early Treatment Diabetic 
Retinopathy Study (ETDRS) [22]. The more seriously 
affected eye was the basis of evaluation of the grade of 
the disease. Diagnosis of DR was made by vitreo-retinal 
fellowships, according to the presence of one or more of 
the following clinical characteristics in the fundus: 
Venous beading, hard or soft exudates, hemorrhages, 
intra-retinal microvascular abnormalities, pre-retinal new 
vessels, cotton wool spots, fibrous proliferation, and 
scars of panretinal photocoagulation. Based on the 
ophthalmologic examination, the participants were 
divided to the following two groups: patients with severe 
severe NPDR and PDR (group 1); and patients without DR 
or mild/moderate NPDR (group 2). Patients with vitreous 
hemorrhage or tractional retinal detachment were 
placed in the first study group. A 10-cc sample of venous 
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blood was withdrawn from each subject, from the cubital 
vein for laboratory assessment. Fasting Blood Sugar 
(FBS), HbA1c, Complete Blood Count (CBC), lipid profile 
containing High Density Lipoprotein (HDL), Low Density 
Lipoprotein (LDL), total cholesterol, triglycerides, renal 
function tests, Erythrocyte Sedimentation Rate (ESR), and 
C Reactive Protein (CRP) were measured, according to a 
standard protocol. The serum level of leptin was assessed 
by the Enzyme Linked Immunosorbent Assay (ELISA) kit 
of Labor Diagnostika Nord Gmbh & Co (LDN). Coefficient 
of Variation (CV) for intra-assay and inter-assay precision 
were reported to be 3.7% to 5.0% and 5.9% to 6.8%, 
respectively. All measurements of leptin were done 
during one session and at the same time, according to 
the manufacturer’s instructions. All the data are 
presented as mean ± Standard Deviation (SD) and 
proportions, as appropriate. The parametric variables 
with normal distribution were compared using 
independent t-test while those without normal 
distribution were compared using the Mann-Whitney U-
test. Proportions were compared using the chi-squared 
test. The linear correlation between the serum level of 
leptin and the anthropometric measures was determined 
by Pearson’s correlation analysis. A multivariate logistic 
regression model was used to measure the influence of 
independent variables (leptin, GFR, Creatinine, TG, total 
cholesterol, Gender, LDL, CRP, and ESR) on the 
dependent variable (retinopathy groups). A two-sided p-
value of less than 0.05 was considered statistically 
significant. This study also reported the correlation 
coefficients for the correlation analysis.  
RESULTS 
Overall, the current research screened 84 patients for 
eligibility, of whom one was not included. Thus, a total of 
83 patients were included.  
 
Table 1: The Baseline Characteristics of Patients with Type 2 Diabetes Mellitus included in the Current Study, in Two Study Groups 
 Group 1 (n = 44) mean ± SD Group 2 (n = 39) mean ± SD P-Value 
*
 
Age (years) 59.3 ± 6.33 58.7 ± 7.69 0.125 
Gender   0.101 
Male (%) 28 (63.4%) 18 (46.2%)  
Female (%) 16 (36.6%) 21 (53.8%)  
Glycemic control   0.701 
Oral medication (%) 22 (54.6%) 22 (56.5%)  
Insulin (%) 20 (45.4%) 17 (43.5%)  
Disease duration   0.133 
≥ 10 years (%) 23 (52.3%) 14 (35.9%)  
< 10 years (%) 19 (47.7%) 25 (64.1%)  
Hb (g/dL) 13.6 ± 1.88 13.83 ± 1.56 0.553 
FBS (mg/dL) 153.93 ± 77.9 159.21 ± 61.8 0.327 
GFR (mL/min/1.73 m
2
) 68.95 ± 24.17 75.24 ± 15.30 0.162 
TG (g/dL) 138.02 ± 63.2 143.63 ± 68.5 0.704 
Cholesterol (mg/dL) 164.21 ± 44.7 153.50 ± 40.36 0.262 
HDL (mg/dL) 45.53 ± 12.7 49.58 ± 47.67 0.351 
LDL (mg/dL) 86.86 ± 32.72 89.89 ± 39.79 0.711 
HbA1c (%) 7.67 ± 2.18 7.26 ± 1.57 0.325 
ESR (mm/hr) 19.98 ± 21.49 10.24 ± 7.91 0.049 
CRP (mg/L) 5.86 ± 16.63 1.42 ± 2.93 0.497 
SBP (mmHg) 139.53 ± 17.34 131.71 ± 15.34 0.025 
DBP (mmHg) 89.30 ± 11.12 85.92 ± 8.37 0.691 
n: Number; SD: Standard Deviation; %: Percentage; FBS: Fasting Blood Sugar; CRP: C-reactive Protein; DBP: Diastolic Blood Pressure; ESR: Erythrocyte 
Sedimentation Rate; GFR: Glomerular filtration rate; Hb: Hemoglobin; HDL: High-density lipoprotein; LDL: Low-density Lipoprotein; SBP: Systolic blood 
pressure; TG: Triglyceride ;g/dl : Grams per Deciliter ; mg/dl : Milligrams per Deciliter ; mg/l: Milligrams per Litre; kg/m2: Kilogram per Square Meter; 
mmHg: Millimeter of Mercury; mm/hr: millimeter per hour; mL/min/1.73 m2: milliliter per minute per 1.73 square meters. 
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Table 2 The Baseline Characteristics of Patients with Type 2 Diabetes Mellitus included in the Current Study in Two Study Groups 
 Group 1 (n = 44)  
mean ± SD 
Group 2 (n = 39)  




Serum leptin (ng/mL) 40.39 ± 33.15 19.29 ± 14.37 0.003 
BMI (kg/m
2
) 29.58 ± 5.33 27.88 ± 4.46 0.167 
BAI (%) 0.343 ± 0.081 0.311 ± 0.047 0.061 
WHR 0.934 ± 0.028 0.943 ± 0.021 0.220 
n: Number ;ng/dl : Nano grams per Deciliter ; kg/m2: Kilogram per Square Meter ; %: Percentage; SD: Standard Deviation; BMI: Body Mass Index; BAI: 
Body Adiposity Index; WHR: Waist-to-Hip Ratio 
* P-Value less than 0.05 are in Bold 
 
 
Figure 1: A 65-year-old male with corrected distance visual acuity of 
40/200 in both eyes with severe non-proliferative diabetic 
retinopathy and CSME categorized in group 1. 
 
 
Figure 2: A 68-year-old male with active proliferative diabetic 
retinopathy and history of previous pan-retinal photo coagulation 
categorized in group 1.  
 
Figure 3:  A 53-year-old female with no diabetic retinopathy 




Figure 4: A 60-year-old male with non-proliferative diabetic 
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The mean age of the participants was 59.3 ± 6.9 (ranging 
from 42 to 78) years. In total, there were 46 (55.4%) 
males and 37 (44.6%) females. Based on the 
ophthalmoscopic examination, 44 (53%) cases were 
included in the PDR group, while 39 (47%) were included 
in the NPDR group. The two study groups were 
comparable regarding baseline characteristics, such as 
age and gender. The baseline characteristics of the two 
study groups are summarized in Table 1. 
As demonstrated, those in group 1 had significantly 
higher ESR (P = 0.049) and systolic blood pressure (P = 
0.025) when compared to those in group 2. The 
comparison between the two study groups, regarding the 
anthropometric measures and the serum leptin level, is 
demonstrated in Table 2. 
The serum level of leptin was found to be significantly 
higher in group 1 when compared to that of group 2 (P = 
0.003). However, the anthropometric measures, 
including BMI (P = 0.167), BAI (P = 0.061), and WHR (P = 
0.220) were comparable between the two study groups. 
The serum level of leptin remained significantly higher in 
group 1 when compared to that of group 2, after 
adjusting for GFR, age, HbA1C, SBP, TG, HDL, LDL, and 
ESR (P = 0.001), though the multivariate logistic 
regression model. Serum leptin level was positively 
correlated with BMI (r = 0.819; P < 0.001) and BAI (r = 
0.630; P < 0.001) in group 1. In group 2, serum leptin 
level had a linear positive correlation with BMI (r = 0.521; 
P = 0.042) and BAI (r = 0.568; P = 0.008). In those with 
PDR, the serum leptin level was also associated with ESR 
(r = 0.423; P = 0.032). Sample color fundus photographs 
of both study groups illustrated in figure 1 to 4. 
DISCUSSION 
In the current study, the researchers compared the 
serum levels of leptin among patients with type 2 DM, 
having various degrees of DR. Higher serum leptin levels 
were found in patients with severe DR (severe NPDR or 
PDR) compared to those with mild to moderate NPDR. 
However, the anthropometric measures, such as BMI and 
BAI, were not found to be associated with severity of DR. 
These results are in line with previous studies that found 
serum and vitreous levels of leptin as an indicator of 
extension of DR in patients with type 2 DM [9, 18, 19]. 
According to the results of the current study, it could be 
suggested that serum leptin level is a more valuable 
marker of DR extension in subjects with type 2 DM and is 
superior to anthropometric measures of obesity. 
Measurement of serum level of leptin is accessible, 
feasible, and inexpensive, and could be available even at 
secondary healthcare centers. Thus, its addition to 
screening programs of patients with type 2 DM could be 
beneficial. Several studies have indicated that leptin has 
the ability to influence CRP expression, both by affecting 
other pro-inflammatory modulators, such as IL6, and by 
promoting its hepatic and vascular production [23, 24]. In 
turn, CRP causes leptin resistance, by changing its 
bioavailability and co-precipitating with this molecule 
[24, 25]. This study measured ESR and CRP, as markers of 
the inflammatory state. The two study groups were 
comparable regarding serum CRP levels. The ESR level 
was significantly higher in patients with more severe DR.  
The current research found a positive correlation 
between ESR and leptin level in patients with PDR. This 
indicates that inflammation plays a role in the 
pathophysiology of DR, separately, or as part of the 
effects of leptin. This might be due to the complex 
endocrine and pro-inflammatory nature of leptin [26]. 
This theory was suggested regarding the increase in the 
strength of correlation between leptin and DR after 
omitting ESR from the equation. Therefore, ESR may be 
considered as an adjunctive factor to leptin rather than a 
confounding one in the pathophysiology of diabetic 
retinopathy. To prove this assumption, further 
investigations are required. Elevated vitreous levels of 
leptin in patients with PDR have been observed in some 
studies [18, 19], yet intraocular production, as a cause of 
this elevation, has been rejected by some others [20]. It 
is not clear whether the increase in vitreous levels of 
leptin is paracrine or is the result of active permissive 
mechanisms [18]. Simultaneous measurement of plasma 
and vitreous leptin is needed for further clarification. 
The measured leptin level was compatible with 
previously measured leptin levels in patients with 
diabetes [13]. Increase in leptin level was associated with 
increased risk of development of DR [9, 13]. In fact, one-
unit increase in leptin increased the chance of having 
more severe stages of retinopathy by 5.4%, which is in 
concordance with previous studies [15]. Multiple studies 
have investigated the correlation of indices, such as BMI, 
WHR,
 
and BAI, as indices of obesity with DR [27-29]. 
Previous studies have shown different results regarding 
BMI. Increased BMI has been protective for DR in some 
instances [29, 30] and predictive of DR in others [31]. 
This research did not find any statistically significant 
differences in BMI, BAI or WHR between the two study 
groups. This may be due to the fact that factors, such as 
calorie intake, physical activity, and lifestyle 
modifications were not taken in account by the current 
study. Although increase in BMI and BAI is associated 
with increase in leptin level, it is not correlated with 
development of retinopathy. This may indicate the effect 
of leptin in DR, as an endocrine hormone. 
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Measurements, such as BMI and BAI, indicate the total 
body fat amount without being able to measure its 
activity as a functional unit. This research found no 
correlation between these measurements and presence 
of more severe stages of DR, which means that total 
body fat was not a risk factor for development of DR in 
the current research. Instead, if one considers fat tissue 
as a functional organ and measures its hormonal activity, 
leptin may be a better indicator. It could be suggested 
that leptin, if not a replacement of BMI and BAI, is a good 
adjunctive measure to these tests for evaluation of fat 
tissue and its effect on retina in diabetes. With the 
increased role of anti-VEGF agents in the treatment of 
diabetic macular edema, certain groups of patients 
showed a less optimal response to these agents [32, 33]. 
This mandates a search for alternative treatment 
pathways. Targeting leptin in this group of patients may 
provide other means of treatment in the future. There 
were a number of limitations in the current study. First, 
the research included a limited number of patients; as a 
case-controlled study, it would be difficult to match the 
patients and the controls, thus, this research applied a 
rigorous inclusion and exclusion criteria to eliminate the 
confounders. A multivariate logistic regression model 
was also employed for this purpose while the power of 
the study was 80%. Further studies with larger study 
populations and prospective nature are required. The 
other limitation was that the researchers did not include 
a control group with normal and non-diabetic patients. 
Finally, the current research did not take daily energy 
expenditure and activity into account, which may have 
influenced the leptin level [13]. Also, there were no 
means of measuring endogenous insulin. Finally, liver 
function was not assessed. These pitfalls should be 
addressed in further studies.  
 
CONCLUSION 
Increased serum level of leptin was associated with 
advanced stages of DR in subjects with type 2 DM. Thus, 
the serum leptin level might be a better indicator of the 
effects of obesity on DR compared to anthropometric 
measures (BAI or BMI). 
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